Becton, Dickinson and Co. traded at $157.25 this Thursday March 26th, decreasing $1.02 or 0.64 percent since the previous trading session. Looking back, over the last four weeks, Becton, Dickinson and Co. lost 10.90 percent. Over the last 12 months, its price fell by 31.24 percent. Looking ahead, we forecast Becton, Dickinson and Co. to be priced at 153.55 by the end of this quarter and at 140.14 in one year, according to Trading Economics global macro models projections and analysts expectations.
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through segments such as BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including medication delivery solutions, medication management solutions, diabetes care and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products.